Targeting phosphatidylserine for Cancer therapy: prospects and challenges.
T lymphocytes
bavituximab
cancer
immunotherapy
phosphatidylserine
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
02
2020
accepted:
13
07
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
29
5
2021
Statut:
epublish
Résumé
Cancer is a leading cause of mortality and morbidity worldwide. Despite major improvements in current therapeutic methods, ideal therapeutic strategies for improved tumor elimination are still lacking. Recently, immunotherapy has attracted much attention, and many immune-active agents have been approved for clinical use alone or in combination with other cancer drugs. However, some patients have a poor response to these agents. New agents and strategies are needed to overcome such deficiencies. Phosphatidylserine (PS) is an essential component of bilayer cell membranes and is normally present in the inner leaflet. In the physiological state, PS exposure on the external leaflet not only acts as an engulfment signal for phagocytosis in apoptotic cells but also participates in blood coagulation, myoblast fusion and immune regulation in nonapoptotic cells. In the tumor microenvironment, PS exposure is significantly increased on the surface of tumor cells or tumor cell-derived microvesicles, which have innate immunosuppressive properties and facilitate tumor growth and metastasis. To date, agents targeting PS have been developed, some of which are under investigation in clinical trials as combination drugs for various cancers. However, controversial results are emerging in laboratory research as well as in clinical trials, and the efficiency of PS-targeting agents remains uncertain. In this review, we summarize recent progress in our understanding of the physiological and pathological roles of PS, with a focus on immune suppressive features. In addition, we discuss current drug developments that are based on PS-targeting strategies in both experimental and clinical studies. We hope to provide a future research direction for the development of new agents for cancer therapy.
Identifiants
pubmed: 32802188
doi: 10.7150/thno.45125
pii: thnov10p9214
pmc: PMC7415799
doi:
Substances chimiques
Phosphatidylserines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9214-9229Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
J Control Release. 2014 Jun 10;183:114-23
pubmed: 24698945
Nat Med. 2019 Jun;25(6):941-946
pubmed: 31171878
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):10886-7
pubmed: 23784781
Cancer Res. 2014 Jan 1;74(1):253-62
pubmed: 24165158
Ann Oncol. 2014 Aug;25(8):1603-8
pubmed: 24827131
Allergy Asthma Proc. 2019 Nov 1;40(6):361
pubmed: 31690369
Cancer Res. 2011 May 15;71(10):3540-51
pubmed: 21430066
Traffic. 2018 Mar;19(3):157-165
pubmed: 29120102
Biomolecules. 2019 Aug 20;9(8):
pubmed: 31434355
PLoS Biol. 2017 Jun 26;15(6):e2002711
pubmed: 28650960
Cell Death Differ. 2016 Jun;23(6):952-61
pubmed: 26891692
Mol Cancer. 2018 Jan 31;17(1):20
pubmed: 29386018
Methods Mol Biol. 2015;1313:141-8
pubmed: 25947662
Nat Cell Biol. 2005 Aug;7(8):808-16
pubmed: 16025105
Otolaryngol Head Neck Surg. 2018 Sep;159(3):581-586
pubmed: 29759032
Lancet Glob Health. 2019 Feb;7(2):e249-e256
pubmed: 30683242
Cell Death Differ. 2008 Jan;15(1):192-201
pubmed: 17962816
Arch Pharm Res. 2019 Jul;42(7):617-628
pubmed: 31172440
Nat Immunol. 2001 Dec;2(12):1109-16
pubmed: 11725301
Pract Radiat Oncol. 2018 May - Jun;8(3):145-152
pubmed: 29545124
Lipid Insights. 2016 Feb 01;8(Suppl 1):41-4
pubmed: 26843813
J Biol Chem. 2011 May 13;286(19):17205-16
pubmed: 21454556
Science. 1993 Oct 29;262(5134):695-700
pubmed: 8235590
J Clin Invest. 2013 Aug;123(8):3231-42
pubmed: 23867499
Exp Cell Res. 2004 Jan 15;292(2):403-16
pubmed: 14697347
Drug Alcohol Depend. 2017 Sep 1;178:136-142
pubmed: 28647681
Cells. 2019 May 02;8(5):
pubmed: 31052568
Cancer Med. 2015 Jul;4(7):1051-9
pubmed: 25826750
N Engl J Med. 2018 Nov 01;379(18):1711-1721
pubmed: 30380386
Cell Commun Signal. 2019 Oct 21;17(1):132
pubmed: 31638994
Nat New Biol. 1972 Mar 1;236(61):11-2
pubmed: 4502419
Oncogene. 2011 Jan 20;30(3):301-12
pubmed: 20818417
Cell Commun Signal. 2020 Feb 22;18(1):29
pubmed: 32087708
Mol Pharm. 2017 Jan 3;14(1):147-156
pubmed: 28043132
Cell Death Dis. 2019 Mar 8;10(3):233
pubmed: 30850582
Transl Oncol. 2015 Jun;8(3):196-203
pubmed: 26055177
J Investig Med. 2019 Dec;67(8):1125-1130
pubmed: 31511310
Oncotarget. 2019 Jan 25;10(8):856-868
pubmed: 30783515
Cell Commun Signal. 2019 Oct 15;17(1):126
pubmed: 31615534
Cancer Immunol Res. 2013 Oct;1(4):256-68
pubmed: 24777853
J Physiol. 1999 Feb 1;514 ( Pt 3):713-8
pubmed: 9882743
Mol Cancer. 2018 Jul 25;17(1):104
pubmed: 30045773
Surg Today. 2018 Apr;48(4):431-438
pubmed: 29110089
Breast Cancer (Dove Med Press). 2018 Mar 22;10:53-67
pubmed: 29606888
mBio. 2017 Sep 26;8(5):
pubmed: 28951472
J Exp Clin Cancer Res. 2018 Mar 5;37(1):44
pubmed: 29506555
Front Immunol. 2017 Nov 10;8:1521
pubmed: 29176978
Physiol Rev. 2016 Apr;96(2):605-45
pubmed: 26936867
J Biol Chem. 2014 Nov 28;289(48):33543-56
pubmed: 25315773
Data Brief. 2018 Jul 29;20:126-131
pubmed: 30109250
Semin Cancer Biol. 2015 Oct;34:46-51
pubmed: 26057207
Jpn J Clin Oncol. 2017 Jan;47(1):54-60
pubmed: 28122892
Proc Natl Acad Sci U S A. 2011 Nov 29;108(48):19246-51
pubmed: 22084121
Biochim Biophys Acta. 2013 Feb;1831(2):429-37
pubmed: 23159415
Front Immunol. 2019 Feb 26;10:292
pubmed: 30863404
Cancer Immunol Res. 2015 Nov;3(11):1269-78
pubmed: 26112921
ISRN Hematol. 2013;2013:614619
pubmed: 23401787
Thromb Res. 2020 Apr;188:5-16
pubmed: 32032826
Nature. 2014 Mar 27;507(7493):508-12
pubmed: 24553136
Oncology (Williston Park). 2019 Apr 15;33(4):141-8
pubmed: 30990567
Biochim Biophys Acta Biomembr. 2018 Oct;1860(10):2126-2133
pubmed: 29920237
Oncol Rep. 2018 Oct;40(4):2115-2126
pubmed: 30106451
Science. 2013 Jul 26;341(6144):403-6
pubmed: 23845944
J Clin Oncol. 2011 Jul 1;29(19):2660-6
pubmed: 21606412
Nat Commun. 2013;4:2367
pubmed: 23996062
Eur J Cancer. 2017 Jan;70:122-132
pubmed: 27914242
Theranostics. 2020 May 1;10(13):5943-5956
pubmed: 32483429
Cell. 2017 Jan 12;168(1-2):239-251.e16
pubmed: 28041850
J Control Release. 2018 Feb 10;271:139-148
pubmed: 29277680
Allergy Asthma Proc. 2013 Jan-Feb;34(1):e21-6
pubmed: 23406933
Clin Lung Cancer. 2016 May;17(3):169-76
pubmed: 27265742
PLoS One. 2012;7(7):e40146
pubmed: 22792231
Biochem J. 2014 Apr 1;459(1):229-39
pubmed: 24467409
Am J Clin Oncol. 2018 Oct;41(10):972-976
pubmed: 28763330
Lancet Haematol. 2019 Sep;6(9):e448-e458
pubmed: 31327689
Cancer Lett. 2019 Aug 28;458:1-12
pubmed: 31132431
Pharmacology. 2020;105(3-4):145-163
pubmed: 31910414
Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1479-84
pubmed: 12459374
Anesth Analg. 2009 May;108(5):1433-46
pubmed: 19372317
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Cell Sci. 2019 Sep 2;132(17):
pubmed: 31371488
Oncoscience. 2015 Feb 09;2(2):102-110
pubmed: 25859553
J Immunol. 2007 May 1;178(9):5635-42
pubmed: 17442946
Physiol Rev. 1991 Jan;71(1):129-53
pubmed: 1986387
Semin Cancer Biol. 2018 Oct;52(Pt 1):17-25
pubmed: 28870843
Mol Cancer. 2019 May 14;18(1):94
pubmed: 31088471
Clin Lung Cancer. 2018 Jul;19(4):e481-e487
pubmed: 29631965
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Clin Cancer Res. 2014 Dec 15;20(24):6452-64
pubmed: 25320356
J Biol Chem. 2009 Nov 20;284(47):32670-9
pubmed: 19778899
FEBS J. 2017 Nov;284(21):3575-3588
pubmed: 28881496
Br J Haematol. 2019 Oct;187(1):e20-e24
pubmed: 31396948
Mol Cancer Ther. 2010 May;9(5):1147-57
pubmed: 20423991
Mol Metab. 2019 Sep;27:33-46
pubmed: 31285171
Eur J Cancer. 2016 Jan;52:50-66
pubmed: 26645943
Cancer Res. 2018 Jun 1;78(11):3002-3013
pubmed: 29531161
Mol Cell. 2017 Jun 1;66(5):635-647.e7
pubmed: 28575659
Mol Ther Nucleic Acids. 2018 Mar 2;10:9-27
pubmed: 29499959
Hum Vaccin Immunother. 2018 Jun 3;14(6):1423-1431
pubmed: 29420117
J Biol Chem. 2017 Nov 24;292(47):19381-19391
pubmed: 28982976
Curr Opin Immunol. 2020 Feb;62:31-38
pubmed: 31837595
Nat Immunol. 2012 Sep;13(9):808-10
pubmed: 22910384
J Immunol. 2019 Aug 15;203(4):990-1000
pubmed: 31263038
Cell Commun Signal. 2019 Oct 29;17(1):139
pubmed: 31665027
Cancer Lett. 2009 Oct 8;283(2):168-75
pubmed: 19401262
Nat Med. 2020 Apr;26(4):577-588
pubmed: 32094924
Biochim Biophys Acta. 1975 Mar 24;380(3):357-69
pubmed: 1169965
Mol Ther Nucleic Acids. 2018 Sep 7;12:405-419
pubmed: 30195778
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9509-14
pubmed: 27503893
Traffic. 2015 Jan;16(1):1-18
pubmed: 25243850
Oncotarget. 2017 Feb 21;8(8):13986-14002
pubmed: 28118606
Lung Cancer. 2014 Nov;86(2):231-6
pubmed: 25236982
Thromb Haemost. 2017 Jun 28;117(7):1265-1271
pubmed: 28594052
Leukemia. 2020 Oct;34(10):2708-2721
pubmed: 32269319
Glycobiology. 2003 May;13(5):339-49
pubmed: 12626425
Theranostics. 2013 Nov 02;3(11):903-13
pubmed: 24312159
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Transl Oncol. 2018 Aug;11(4):1044-1052
pubmed: 29982102
Lipids. 1984 Mar;19(3):171-8
pubmed: 6717248
J Biol Chem. 2014 Sep 12;289(37):25750-63
pubmed: 25074926
Front Immunol. 2015 May 05;6:212
pubmed: 25999950
Theranostics. 2020 Jan 12;10(5):2029-2046
pubmed: 32089734
Lancet Haematol. 2019 Sep;6(9):e480-e488
pubmed: 31400961
Theranostics. 2020 Feb 19;10(8):3652-3667
pubmed: 32206114
Science. 2008 Jan 11;319(5860):210-3
pubmed: 18187657
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
Blood. 2006 Dec 15;108(13):4094-101
pubmed: 16912227
Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2907-2912
pubmed: 30718401
Eur J Pharm Biopharm. 2020 Feb;147:87-101
pubmed: 31899369
Mol Ther. 2013 Aug;21(8):1517-25
pubmed: 23732993
Int J Dermatol. 2017 Oct;56(10):e203-e204
pubmed: 28626901
Nat Rev Cancer. 2020 Apr;20(4):218-232
pubmed: 32024970
Cell Death Dis. 2018 Feb 28;9(3):329
pubmed: 29491386
Nat Commun. 2018 May 24;9(1):2049
pubmed: 29799007
Immunol Rev. 2010 May;235(1):172-89
pubmed: 20536563
Nature. 2007 Nov 15;450(7168):430-4
pubmed: 17960134
Cell Commun Signal. 2020 Jan 9;18(1):6
pubmed: 31918715
Biochim Biophys Acta Mol Cell Res. 2017 Dec;1864(12):2261-2271
pubmed: 28844836
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Hum Reprod. 2016 Apr;31(4):700-11
pubmed: 26908841
Cell Death Differ. 2016 Jun;23(6):962-78
pubmed: 26915293
Biochim Biophys Acta. 2013 Mar;1831(3):543-54
pubmed: 22960354
J Immunol. 2010 Feb 15;184(4):1918-30
pubmed: 20083673
Cancer Cell. 2016 May 9;29(5):653-668
pubmed: 27117758
Front Oncol. 2019 Oct 22;9:1116
pubmed: 31696059
J Cancer Ther. 2012 Aug;3(4):321-326
pubmed: 25485166
J Spinal Cord Med. 2018 Sep;41(5):529-543
pubmed: 29400988
Immunology. 2006 Apr;117(4):433-42
pubmed: 16556256
Ann Surg Oncol. 2016 Dec;23(Suppl 5):583-591
pubmed: 26847681
Nat Commun. 2016 Feb 17;7:10501
pubmed: 26883990
Cancer Manag Res. 2019 Jun 17;11:5537-5543
pubmed: 31354358
Clin Cancer Res. 2011 Nov 1;17(21):6888-96
pubmed: 21989064
EMBO J. 2015 Mar 4;34(5):669-88
pubmed: 25595798
Cancer Immunol Res. 2019 Sep;7(9):1472-1484
pubmed: 31266785
Front Immunol. 2020 Jan 28;11:18
pubmed: 32082311
J Cell Sci. 2001 Oct;114(Pt 20):3631-42
pubmed: 11707515
Biochim Biophys Acta. 2014 Feb;1843(2):275-87
pubmed: 24286866
J Biomed Opt. 2016 Dec 1;21(12):126002
pubmed: 27918799
Nature. 2002 Jan 31;415(6871):536-41
pubmed: 11823861
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Biol Chem. 2014 Oct 31;289(44):30257-67
pubmed: 25231987
Mol Cancer Ther. 2018 Jan;17(1):169-182
pubmed: 28939556
Vaccine. 2011 Jun 24;29(29-30):4785-93
pubmed: 21557977
Sci Transl Med. 2013 Aug 28;5(200):200ra116
pubmed: 23986400
J Biol Chem. 2005 Dec 2;280(48):40032-40
pubmed: 16192276
Oncoimmunology. 2018 Feb 20;7(6):e1434467
pubmed: 29872573
J Cell Sci. 2009 Sep 15;122(Pt 18):3365-73
pubmed: 19726632
Clin Cancer Res. 2015 Feb 15;21(4):687-92
pubmed: 25501578
Ann Oncol. 2018 Jan 1;29(1):71-83
pubmed: 29069302
Cell Death Dis. 2018 Feb 28;9(3):328
pubmed: 29491402
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7
pubmed: 22451913
Immunol Rev. 2017 Mar;276(1):97-111
pubmed: 28258697
Cell Death Differ. 2007 Jul;14(7):1237-43
pubmed: 17431418
Theranostics. 2017 Sep 26;7(17):4149-4167
pubmed: 29158816
Clin Lung Cancer. 2020 Jan;21(1):e25-e29
pubmed: 31690489
J Leukoc Biol. 2015 Apr;97(4):751-60
pubmed: 25624460
Br J Haematol. 2005 Sep;130(5):759-67
pubmed: 16115134
Cancers (Basel). 2016 Mar 15;8(3):
pubmed: 26999211
Science. 2015 Jul 24;349(6246):432-6
pubmed: 26206936
Nature. 2013 May 9;497(7448):263-7
pubmed: 23615608
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Trends Microbiol. 2020 Mar;28(3):224-235
pubmed: 31732320
Cancer Lett. 2011 Feb 28;301(2):177-84
pubmed: 21194833
PLoS Genet. 2019 Dec 23;15(12):e1008548
pubmed: 31869331
Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):93-103
pubmed: 32311417
Ann Oncol. 2018 Jul 1;29(7):1548-1553
pubmed: 29767677
J Immunol. 2015 Feb 15;194(4):1602-8
pubmed: 25582854
J Cell Mol Med. 2019 Aug;23(8):4900-4912
pubmed: 31232522
Cold Spring Harb Perspect Biol. 2015 Dec 01;7(12):
pubmed: 26626938